CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue:      
Total revenue $ 43,165,527 $ 41,004,601 $ 24,949,473
Cost of revenue 11,047,350 11,052,409 7,363,919
Gross profit 32,118,177 29,952,192 17,585,554
Operating expenses:      
Research and development 16,380,930 8,810,561 12,091,797
Legal, financial and other consulting 2,731,515 3,048,242 2,462,151
Selling, general and administrative 35,750,477 28,463,723 22,005,670
Total operating expenses 54,862,922 40,322,526 36,559,618
Loss from operations (22,744,745) (10,370,334) (18,974,064)
Other income (expense):      
Interest (expense), net 28,007 (1,201,067) (1,033,661)
Gain/(loss) on foreign currency transactions (2,577,913) 2,607,139 (350,365)
Total other income (expense), net (2,549,906) 1,406,072 (1,384,026)
Loss before benefit from income taxes (25,294,651) (8,964,262) (20,358,090)
Benefit from income taxes 736,003 1,127,074 1,092,446
Net loss attributable to common shareholders $ (24,558,648) $ (7,837,188) $ (19,265,644)
Basic net loss per common share $ (0.57) $ (0.20) $ (0.60)
Diluted net loss per common share $ (0.57) $ (0.20) $ (0.60)
Weighted average number of shares of common stock outstanding, basic 43,359,186 38,818,990 32,255,253
Weighted average number of shares of common stock outstanding, diluted 43,359,186 38,818,990 32,255,253
Comprehensive loss:      
Net loss $ (24,558,648) $ (7,837,188) $ (19,265,644)
Other comprehensive income (loss):      
Currency translation adjustment 2,259,663 (2,260,056) 237,803
Comprehensive loss (22,298,985) (10,097,244) (19,027,841)
Product      
Revenue:      
Total revenue 40,108,567 39,452,502 22,765,854
Cyto Sorb Sales      
Revenue:      
Total revenue 39,996,700 39,342,102 22,545,754
Other Sales      
Revenue:      
Total revenue 111,867 110,400 220,100
Grant      
Revenue:      
Total revenue $ 3,056,960 $ 1,552,099 $ 2,183,619